Aurobindo has entered into an agreement to acquire Sandoz' (generics/biosimilars arm of Novartis) US dermatology and oral solid businesses (300 products including generic and branded products and three plants) for a consideration of US$900 million. The transaction will be financed entirely by debt. According to the management, the transaction is expected to be accretive to normalise EPS from the first full year of acquisition. The acquisition is expected to be closed in CY19. The acquisition is at 1x (after adjustment) of sales, which is one of the...